A Phase 2 Time Limited Approach Based on Depth of Response to Front-Line Acalabrutinib in Combination With Obinutuzumab for CLL/SLL Patients Who Achieve Complete Remission or Partial Remission With Undetectable Minimal Residual Disease
Latest Information Update: 20 Aug 2024
At a glance
- Drugs Acalabrutinib (Primary) ; Obinutuzumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 16 Aug 2023 Planned End Date changed from 1 Feb 2024 to 1 Feb 2025.
- 16 Aug 2023 Planned primary completion date changed from 1 Feb 2024 to 1 Feb 2025.
- 27 Mar 2023 Planned End Date changed from 1 Feb 2023 to 1 Feb 2024.